{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:58:46Z","timestamp":1775311126423,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute for Health Research Cardiovascular Biomedical Research Unit"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jacl.2019.06.009","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T06:10:28Z","timestamp":1562047828000},"page":"788-796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial"],"prefix":"10.1016","volume":"13","author":[{"given":"Tina Z.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa J.","family":"Arachchillage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefin","family":"Ahnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston","family":"Banya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Pottle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Barbir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dudley J.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2019.06.009_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.009_bib2","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.009_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5339\/gcsp.2015.28","article-title":"High prevalence of raised lipoprotein(a) in patients with refractory angina","volume":"2","author":"Khan","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.jacl.2019.06.009_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man: the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"7","key":"10.1016\/j.jacl.2019.06.009_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11936-017-0549-z","article-title":"Lipoprotein(a): a lipoprotein whose time has come","volume":"19","author":"Kelly","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"32","key":"10.1016\/j.jacl.2019.06.009_bib6","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.009_bib7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.06.009_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2019.06.009_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2362.1994.tb02373.x","article-title":"Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)","volume":"24","author":"Cremer","year":"1994","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.1016\/j.jacl.2019.06.009_bib10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2013-304902","article-title":"Lipoprotein(a): the underestimated cardiovascular risk factor","volume":"100","author":"Thompson","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacl.2019.06.009_bib11","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.009_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.transci.2009.05.014","article-title":"Comparison of different Lp(a) elimination techniques: a retrospective evaluation","volume":"41","author":"Borberg","year":"2009","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jacl.2019.06.009_bib13","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Klingel R for the Pro(a)LiFe Study Group. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease. Prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.06.009_bib14","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"20","key":"10.1016\/j.jacl.2019.06.009_bib15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.009_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.009_bib17","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2019.06.009_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jacl.2019.06.009_bib19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus\u2014Integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefannuti","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2019.06.009_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccl.2015.02.002","article-title":"Lipoprotein apheresis","volume":"33","author":"Moriarty","year":"2015","journal-title":"Cardiol Clin"},{"issue":"8","key":"10.1016\/j.jacl.2019.06.009_bib21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.amjcard.2003.12.059","article-title":"Effect of low-density lipoprotein cholesterol apheresis on blood viscosity","volume":"93","author":"Moriarty","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2019.06.009_bib22","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2015.02.040","article-title":"Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk","volume":"65","author":"Okafor","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacl.2019.06.009_bib23","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2019.06.009_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1160\/TH16-09-0712","article-title":"Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention","volume":"117","author":"Christopoulos","year":"2017","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jacl.2019.06.009_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11789-017-0089-9","article-title":"The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on","volume":"12","author":"Schettler","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"issue":"1","key":"10.1016\/j.jacl.2019.06.009_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12916-017-0787-7","article-title":"Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials","volume":"15","author":"Sahebkar","year":"2017","journal-title":"BMC Med"},{"issue":"9965","key":"10.1016\/j.jacl.2019.06.009_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacl.2019.06.009_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2019.06.009_bib29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2019.06.009_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10557-016-6654-5","article-title":"Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease","volume":"30","author":"Stein","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10002","key":"10.1016\/j.jacl.2019.06.009_bib31","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsmikas","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2019.06.009_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0049-3848(94)90246-1","article-title":"Fibrin deposition and fibrin degradation products in atherosclerotic plaques","volume":"75","author":"Smith","year":"1994","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacl.2019.06.009_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-3083.2012.02734.x","article-title":"LDL apheresis and inflammation \u2013 implications for atherosclerosis","volume":"76","author":"Hovland","year":"2012","journal-title":"Scand J Immunol"},{"issue":"3","key":"10.1016\/j.jacl.2019.06.009_bib34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5301\/IJAO.2011.6469","article-title":"Prothrombotic changes in platelet, endothelial and coagulation function following hemodialysis","volume":"34","author":"Milburn","year":"2011","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.jacl.2019.06.009_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0038-1646768","article-title":"Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay","volume":"59","author":"Pelzer","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacl.2019.06.009_bib36","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/clinchem\/40.10.1962","article-title":"Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2","volume":"40","author":"Greenberg","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2019.06.009_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1744-9987.12056","article-title":"Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis","volume":"18","author":"Yuasa","year":"2014","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jacl.2019.06.009_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood.V54.3.694.694","article-title":"The hemostatic imbalance of plasma-exchange transfusion","volume":"54","author":"Flaum","year":"1979","journal-title":"Blood"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T02:55:56Z","timestamp":1610160956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287419302296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1933287419302296"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2019.06.009","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2019.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}